WHO IS BREATH THERAPEUTICS?

People living with rare lung diseases are at the center of everything we do.

Founded in 2016
Became a Zambon company in July 2019

focused on innovative inhalation therapies for respiratory orphan diseases

20+
employees with expertise in drug formulation, aerosol drug delivery, clinical development & commercialization

Our respiratory product is in Phase 3 development

Clinical trials underway in US and Europe

For more information please visit breath-therapeutics.com
WHAT IS BRONCHIOLITIS OBLITERANS SYNDROME?

Bronchiolitis Obliterans Syndrome (BOS) was first described in the 1950’s. It is often associated with lung transplant and allogeneic hematopoietic stem cell transplant.

There is no approved therapy.

BOS is a life-threatening disease.

WHERE the immune system attacks the small airways of the lungs causing obstruction of the airways.

Respiratory failure or death within 2 to 4 years of diagnosis.

BOS affects an estimated 30,000 people in US, EU, and Japan.

BOS has really been the Achilles heel of lung transplantation.

It’s the leading cause of death beyond the first year after transplantation.

Ramsey Hachem, MD, Washington University in St. Louis and Barnes-Jewish Hospital.

BOS affects Adults and Children.

For more information please visit breath-therapeutics.com
WHAT IS LIPOSOMAL CYCLOSPORINE A FOR INHALATION (L-CsA-i*)?

Cyclosporine is a well known immunosuppressive drug

L-CsA-i is a liposomal formulation of cyclosporine A developed for inhalation use

We combined L-CsA-i with an investigational customized nebulizer. Designed for home inhalation

The rationale of inhaled therapies: Deliver drug directly to the lungs WITH lower systemic exposure

BOSTON PROGRAM
Breath’s clinical program with 5 clinical trials is evaluating L-CsA-i as a first potential therapy for BOS.

* L-CsA-i is an investigational drug and its safety and efficacy have not been established

For more information please visit breath-therapeutics.com